INmune Bio Inc. is a biotechnology company focused on developing innovative immunotherapies for the treatment of cancer and neurodegenerative diseases. The company was founded in 2015 and is headquartered in La Jolla, California. Their mission is to harness the power of the immune system to fight diseases that currently have limited treatment options.
INmune Bio's primary focus is on developing therapeutic candidates that target innate immunity, which plays a crucial role in the body's response to cancer and neurodegenerative diseases. Their approach involves modulating specific components of the immune system to enhance its ability to recognize and eliminate abnormal cells or proteins associated with these diseases.
The company's lead product candidate, INB03, is being developed as a potential treatment for cancer. It is a first-in-class monoclonal antibody that selectively targets a specific protein called CD47, which is overexpressed on cancer cells. By blocking the CD47 protein, INB03 aims to enable the immune system to better recognize and destroy cancer cells.
INmune Bio also has a pipeline of product candidates targeting neuroinflammation, a common factor in neurodegenerative diseases such as Alzheimer's and Parkinson's. These candidates aim to modulate the immune response in the brain and reduce inflammation, potentially slowing disease progression and improving patient outcomes.
In February 2019, INmune Bio went public on the NASDAQ stock exchange under the ticker symbol "INMB." The initial public offering (IPO) allowed the company to raise funds to support the development of its pipeline and further advance its clinical programs.
Since going public, INmune Bio has continued to advance its pipeline and conduct clinical trials to evaluate the safety and efficacy of its product candidates. The company is committed to leveraging the potential of immunotherapies to address unmet medical needs and improve the lives of patients affected by cancer and neurodegenerative diseases.